https://allsci.com/news/earnings-call-insights/gilead-q2-earnings-guidance-raises-full-year-on-8/ AllScien 2026-08-05T14:17:35.724804Z Gilead Q2'26: BIC/LEN nears approval as weekly HIV pipeline expands https://allsci.com/news/earnings-call-insights/amgen-amg-513-discontinuation-discontinues/ AllScien 2026-08-05T13:57:06.315267Z Amgen Q2'26: MariTide strategy sharpens as AMG 513 exits pipeline https://allsci.com/news/grants/alzheimers-drug-development-grant-university-of/ AllScien 2026-08-05T13:28:44.425237Z USC wins NIA funding to advance first brain-penetrant cPLA2 inhibitors for Alzheimer's https://allsci.com/news/grants/alzheimers-disease-research-grant-weill-cornell/ AllScien 2026-08-05T13:25:07.363658Z Weill Cornell advances mitochondrial ROS inhibitors for Alzheimer's with NIA grant https://allsci.com/news/grants/antimicrobial-resistant-infection-therapeutics/ AllScien 2026-08-05T13:21:48.316353Z RevaGenix lands USD 12.1m NIAID contract to advance AMR therapeutics https://allsci.com/news/grants/ai-designed-proteins-stem-cells-university-of/ AllScien 2026-08-05T13:17:10.569872Z University of Washington secures NIH funding for AI-guided islet cell engineering https://allsci.com/news/grants/microrna-lung-cancer-therapeutics-uc-davis/ AllScien 2026-08-05T13:14:24.622040Z UC Davis advances bacterial-made microRNA therapy with renewed NCI funding https://allsci.com/news/licensing-and-partnerships/phylo-biomni-lab-chugai-deploys-across-chugais/ AllScien 2026-08-05T12:12:03.459740Z Chugai signs up for Phylo's Biomni Lab agentic AI drug discovery platform https://allsci.com/news/licensing-and-partnerships/cardiac-gene-therapy-partnership-iqvia-with/ AllScien 2026-08-05T12:01:45.673740Z IQVIA to support Medera's cardiac gene therapy and human organoid platform https://allsci.com/news/funding/grace-therapeutics-gtx-104-funding-raises-usd-10m/ AllScien 2026-08-05T11:40:39.706865Z Grace Therapeutics raises USD 10m to fund manufacturing strategy for NDA resubmission https://allsci.com/news/clinical-trials/il-15-superagonist-clinical-trial-forlong/ AllScien 2026-08-05T10:31:21.082964Z Forlong moves SC IL-15 superagonist into Phase I in Australia https://allsci.com/news/clinical-trials/bundibugyo-ebolavirus-vaccine-moderna-launches/ AllScien 2026-08-05T10:23:59.032113Z Moderna advances Bundibugyo Ebola mRNA vaccine into Phase I https://allsci.com/news/regulatory/fda-priority-review-voucher-plozasiran-arrowhead/ AllScien 2026-08-05T09:58:01.993663Z Arrowhead nabs FDA priority review voucher for plozasiran https://allsci.com/news/clinical-trials/merck-sac-tmt-lung-cancer-advances-into/ AllScien 2026-08-05T09:44:57.674426Z Merck Q2'26: Sac-TMT Phase III win prompts rethink of first-line NSCLC strategy https://allsci.com/news/earnings-call-insights/pfizer-2026-guidance-earnings-raises-on/ AllScien 2026-08-05T09:27:45.110072Z Pfizer Q2'26: Mevrometostat, tilrekimig and sigvotatug vedotin shape pipeline outlook https://allsci.com/news/clinical-trials/zasocitinib-sotyktu-psoriasis-takedas-beats/ AllScien 2026-08-04T16:48:30.687046Z Takeda Q1 FY2026: Zasocitinib, TAK-928 and mezagitamab drive pipeline update https://allsci.com/news/grants/pancreatic-cancer-t-cell-engager-oncotab-secures/ AllScien 2026-08-04T16:38:06.483455Z UNC Charlotte spinout OncoTab wins grant to advance tMUC1 TCE for pancreatic cancer https://allsci.com/news/clinical-trials/daiichi-sankyo-datroway-lung-cancer-pushes/ AllScien 2026-08-04T16:31:11.455912Z Daiichi Sankyo Q1 FY2026: Datroway delay, R-DXd uncertainty and CD25 ADC debut https://allsci.com/news/first-in-human-trials/tri-specific-t-cell-engager-autoimmune-enters/ AllScien 2026-08-04T16:16:10.284745Z Leads Biolabs' NewCo Oblenio advances CD19×BCMA×CD3 trispecific into clinic https://allsci.com/news/funding/ocular-immunology-funding-cirrus-therapeutics/ AllScien 2026-08-04T15:49:35.444584Z Cirrus adds SERI, Duke-NUS collaboration and extends seed financing https://allsci.com/news/research/dendritic-cell-cancer-vaccine-case-western-1/ AllScien 2026-08-04T15:42:10.115993Z Researchers harness pre-existing COVID-19 immunity to boost experimental cancer vaccine https://allsci.com/news/research/exhausted-t-cells-lymph-nodes-tianjin-medical/ AllScien 2026-08-04T15:37:52.945904Z Tumor-distal lymph nodes may preserve immune reservoir supporting checkpoint therapy in NSCLC https://allsci.com/news/licensing-and-partnerships/photocure-asieris-milestone-payment-dispute/ AllScien 2026-08-04T15:29:09.575513Z Photocure and Asieris clash over USD 11m China milestone for Cevira approval https://allsci.com/news/regulatory/parkinsons-cell-therapy-fda-grants-fast-track/ AllScien 2026-08-04T14:35:12.972207Z XellSmart's off-the-shelf Parkinson's cell therapy gets FDA fast-track treatment https://allsci.com/news/licensing-and-partnerships/bispecific-adc-licensing-deal-pathos-ai-secures-1/ AllScien 2026-08-04T13:54:30.277628Z Pathos AI commits to USD 2.2b deal for first-in-class TROP2/HER3 bispecific ADC from Alphamab https://allsci.com/news/approvals/pluvicto-prostate-cancer-approval-fda-approves-in/ AllScien 2026-08-04T12:44:03.080508Z FDA approves Pluvicto in earlier-stage prostate cancer, expanding Novartis's radioligand franchise https://allsci.com/news/regulatory/orphan-drug-designation-neuroendocrine-carcinomas/ AllScien 2026-08-04T12:20:33.306700Z Zai Lab's zoci takes FDA orphan drug designation for neuroendocrine carcinomas https://allsci.com/news/ipo-public-listing/blossomhill-therapeutics-ipo-prices-usd-125m-to/ AllScien 2026-08-04T11:11:47.903473Z BlossomHill unveils USD 125m IPO terms as lead EGFR program advances https://allsci.com/news/licensing-and-partnerships/er-protac-breast-cancer-pathos-ai-gains/ AllScien 2026-08-04T09:35:03.342583Z AstraZeneca licenses preclinical ERα PROTAC AZD4241 to Pathos AI https://allsci.com/news/clinical-trials/sibeprenlimab-igan-kidney-function-otsukas/ AllScien 2026-08-04T09:26:41.482485Z Otsuka's sibeprenlimab stabilizes kidney function decline to near-baseline rate in IgAN Phase III https://allsci.com/news/regulatory/orelabrutinib-mesutoclax-china-breakthrough/ AllScien 2026-08-04T08:46:32.004943Z China grants breakthrough status for InnoCare's orelabrutinib-mesutoclax combo in MZL https://allsci.com/news/clinical-trials/breast-cancer-dual-inhibitor-clinical-trial/ AllScien 2026-08-04T08:34:50.804613Z Roche partners with Evexta Bio to test dual-node inhibitor against resistant breast cancer https://allsci.com/news/clinical-trials/lsd-analog-cluster-headache-ceruvia-funds-phase/ AllScien 2026-08-04T08:06:51.042606Z Ceruvia funds Phase I/II trial of non-hallucinogenic LSD analog for cluster headache https://allsci.com/news/pipe-financing/obsidian-til-therapy-melanoma-raises-usd-350m-to/ AllScien 2026-08-03T17:35:22.357246Z Obsidian completes Galera reverse merger and USD 350m PIPE raise https://allsci.com/news/patents-ip/alc1-inhibitors-parp-eisbach-bio-publishes-us-1/ AllScien 2026-08-03T17:32:53.721295Z Eisbach Bio patent application outlines allosteric ALC1 strategy for PARP combinations https://allsci.com/news/clinical-trials/mrna-car-t-hepatocellular-carcinoma-cellorigin/ AllScien 2026-08-03T17:14:51.837933Z CellOrigin advances in vivo mRNA CAR-T for HCC with Walvax partnership https://allsci.com/news/regulatory/fda-fast-track-peanut-allergy-immunotherapy/ AllScien 2026-08-03T16:36:09.988035Z Aravax secures FDA Fast Track designation for PVX108 peanut allergy immunotherapy https://allsci.com/news/funding/annamycin-aml-trial-funding-moleculin-raises-usd/ AllScien 2026-08-03T16:01:35.319797Z Moleculin raises USD 9.3m to fund Annamycin's pivotal AML trial through interim readout https://allsci.com/news/licensing-and-partnerships/tadekinig-alfa-us-commercialization-nippon/ AllScien 2026-08-03T14:54:24.205810Z Nippon Shinyaku exercises USD 30 million option for AB2 Bio's rare disease biologic https://allsci.com/news/business/supernus-indivior-merger-and-to-build-usd-22/ AllScien 2026-08-03T14:36:27.060202Z Supernus, Indivior agree all-stock merger to create diversified CNS biopharma